trial
as of 2026-07-01Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
NCTId NCT06041646
at a glance
Phase 4 · Completed
Enrollment 29 (actual)
Sponsored by BioXcel Therapeutics Inc
Primary completion 2024-04-29
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-10-02
Primary completion
2024-04-29
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
BioXcel Therapeutics IncLead Sponsor
Lotus Clinical Research, LLCCollaborator
Investigators
1
Robert Risinger, MDStudy Chair
Sites
2 total
Little Rock, United StatesRogers, United States
Facts & assertions
4 sourced
Enrollment
29
Phase
PHASE4
Primary Completion Date
2024-04-29
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
company
collaborator
company
indication
investigator
person